These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33482831)

  • 1. Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis.
    Rajabi A; Sharafi H; Alavian SM
    Harm Reduct J; 2021 Jan; 18(1):12. PubMed ID: 33482831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis.
    Rostam-Abadi Y; Rafiemanesh H; Gholami J; Shadloo B; Amin-Esmaeili M; Rahimi-Movaghar A
    Harm Reduct J; 2020 Oct; 17(1):81. PubMed ID: 33087141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis.
    Rahimi J; Gholami J; Amin-Esmaeili M; Fotouhi A; Rafiemanesh H; Shadloo B; Rahimi-Movaghar A
    Addiction; 2020 Apr; 115(4):605-622. PubMed ID: 31631425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.
    Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J
    Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa.
    Mahmud S; Mumtaz GR; Chemaitelly H; Al Kanaani Z; Kouyoumjian SP; Hermez JG; Abu-Raddad LJ
    Addiction; 2020 Jul; 115(7):1244-1262. PubMed ID: 32009283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of the prevalence of hepatitis C virus infection in people who inject drugs in Iran.
    Behzadifar M; Behzadifar M; Bragazzi NL
    BMC Public Health; 2020 Jan; 20(1):62. PubMed ID: 31937278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection.
    Artenie AA; Hickman M; Vickerman P; Stone J; Grebely J; Bruneau J
    Int J Drug Policy; 2021 Oct; 96():103419. PubMed ID: 34452807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risky injection practices and HCV awareness in Chiang Mai Province, Thailand: a respondent-driven sampling study of people who inject drugs.
    Prouté M; Le Coeur S; Tiv MH; Dub T; Jongpaijitsakul P; Ratnamhin A; Angkurawaranon C; Aramrattana A; Lallemant M
    BMC Public Health; 2020 Sep; 20(1):1450. PubMed ID: 32972359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
    Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
    BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants.
    Folch C; Saludes V; Reyes-Ureña J; Antuori A; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2021 Apr; 90():103057. PubMed ID: 33310634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).
    Malekinejad M; Navadeh S; Lotfizadeh A; Rahimi-Movaghar A; Amin-Esmaeili M; Noroozi A
    Int J Infect Dis; 2015 Nov; 40():116-30. PubMed ID: 26460088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis.
    Syangbo A; Hickman M; Colledge-Frisby S; Leung J; Grebely J; Larney S; Degenhardt L; Trickey A
    Drug Alcohol Rev; 2023 Mar; 42(3):569-581. PubMed ID: 36600489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus Seroprevalence in Persons Who Inject Drugs in Korea, 2012-2022: A Multicenter, Retrospective Study.
    Kim J; Choi GH; Jang OJ; Chon Y; Cho SN; Kwon D; Jeong SH
    J Korean Med Sci; 2023 Dec; 38(48):e357. PubMed ID: 38084024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review.
    Colledge S; Leung J; Grebely J; Degenhardt L; Peacock A; Hickman M; Vickerman P; Stone J; Trickey A; Larney S
    Drug Alcohol Depend; 2020 Apr; 209():107899. PubMed ID: 32086179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the impact of a police education program on hepatitis C virus transmission and disease burden among people who inject drugs in Tijuana, Mexico: A dynamic modeling analysis.
    Rivera Saldana CD; Abramovitz D; Beletsky L; Borquez A; Kiene S; Marquez LK; Patton T; Strathdee S; Zúñiga ML; Martin NK; Cepeda J
    Addiction; 2023 Sep; 118(9):1763-1774. PubMed ID: 37039246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
    Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.